Last updated: June 14, 2026
BSS PLUS pharmaceutical suppliers: Who manufactures the drug, active ingredients, and key packaging?
Executive summary: Insufficient information is available to identify the correct pharmaceutical product “BSS PLUS,” its active pharmaceutical ingredient (API), dosage form, strength, strength-specific packaging configuration, and the associated FDA/Orange Book label. Without product identity (e.g., manufacturer name on the market, API, NDC), it is not possible to produce a complete, accurate supplier map across API, contract manufacturing, packaging, and distribution.
What companies supply “BSS PLUS” tablets, capsules, or syrup?
Featured snippet: No supplier list can be stated for “BSS PLUS” because the product’s regulated identity (API + dosage form + strength) is not specified and multiple unrelated products can share similar branded naming.
What supplier types exist in the BSS PLUS supply chain?
- API manufacturers (primary chemical synthesis and purification)
- Drug product manufacturers (CDMOs/MAHs) (formulation, blending, granulation, filling/finishing)
- Packaging suppliers (blister, bottles, cartons, printed pharmacy labels)
- Quality and regulatory testing vendors (stability, microbiology, analytical methods)
- Cold chain or controlled storage vendors (only if the product requires it)
- Distributors and wholesalers (importers and regional distributors)
Which API suppliers make the active ingredient in BSS PLUS?
Featured snippet: Cannot be determined because the active ingredient(s) for “BSS PLUS” is not established.
Common API supplier landscape by therapeutic class
- Antibiotics: fermentation or chemical synthesis specialists
- Cardiometabolic: API polymorph and impurity control vendors
- Pain/anti-inflammatory: scale-up synthesis and solvent-recovery manufacturers
- Multivitamin/mineral or herbal blends: composite sourcing and standardization testing providers
What contract manufacturers (CDMOs) produce BSS PLUS drug product?
Featured snippet: Cannot be identified because “BSS PLUS” lacks a uniquely identified dosage form, strength, and marketing authorization/label.
Where CDMO attribution is typically found
- Marketing authorization dossier (MAA/NDA)
- Pack labeling and lot release documentation
- FDA drug product listing (if applicable)
- Country-specific registration files
- Serialized packaging (where required)
What packaging suppliers provide blister and bottle components for BSS PLUS?
Featured snippet: Cannot be specified without the marketed dosage form and packaging format.
Packaging components that are usually supplier-sourced
- PVC/Alu blisters or PVDC-aluminum
- HDPE bottles with induction seals
- Child-resistant closures
- Desiccant/silica packets (if required by stability)
- Cartons and leaflets with local language labeling
How many suppliers can BSS PLUS use across regions or countries?
Featured snippet: Cannot be quantified because the number of marketed presentations and authorized manufacturers depends on the jurisdiction and product registration set.
Regional variability drivers
- Local regulatory requirements for batch release and GMP inspection
- Need for localized labeling and packaging
- Import vs local manufacturing strategies
- Wholesaler network coverage requirements
How does the manufacturer of BSS PLUS compare with alternative brands?
Featured snippet: No direct comparison is possible because competitor brands and the exact “BSS PLUS” formulation are not defined.
What regulatory filings reveal the BSS PLUS supplier identity?
Featured snippet: Cannot be mapped to specific filings without the correct product identity (label name, NDC/MA number, active ingredient, and dosage form).
Typical jurisdictions where supplier details are found
- FDA (Drug Registration and Listing, Orange Book where applicable)
- EMA (if centralized)
- MHRA (UK)
- Health Canada, TGA, ANVISA, CDSCO, etc.
What supplier risk exists if BSS PLUS needs single-source components?
Featured snippet: Not assessable because the supply chain architecture (number of approved API sites, alternate drug product sites, packaging substitution rules) is not provided.
Risk categories
- API site single-source risk
- Finished dose form equipment constraints
- Packaging component shortages (specialty foils/closures)
- Quality system incompatibilities or audit findings
Key Takeaways
- “BSS PLUS” supplier mapping cannot be completed without identifying the exact regulated product identity (API, dosage form, strength, and marketed labeling/NDC or equivalent).
- Supplier attribution requires a confirmed link to regulatory listings or market labeling that names the MAH/manufacturer and the dosage form/pack presentation.
- Once identity is fixed, the supplier map should cover API sites, CDMOs/MAHs, packaging vendors, testing labs, and distributors by geography.
FAQs
- How do I identify the API supplier for a branded product when the label lists only the brand name?
- Where on regulatory databases is the manufacturer of record for a specific dosage form usually listed?
- Do CDMOs and MAHs change between regions for the same brand name?
- How can packaging vendors be inferred from product blister or bottle appearance when batch codes are present?
- What documents typically confirm contract manufacturing for marketed solid oral dosage forms?
References
- FDA. Drug Registration and Listing (DRLS) system. U.S. Food and Drug Administration.
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
